Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bruker reports robust 2022 performance, eyes growth amid challenges

Bruker's strong financial performance in 2022, driven by organic revenue growth and strategic investments, positions the company for continued success.
While facing supply chain challenges and geopolitical risks, Bruker remains optimistic about growth opportunities in proteomics and spatial biology.
Confidence in 2023 outlook is supported by strong bookings, backlog visibility, and expectations of solid organic growth in key markets.

Bruker reports strong Q1 earnings, eyes spatial biology markets

Bruker's Q1 2023 performance showcased robust revenue growth and margin improvement, with strong demand across key segments and regions.
While facing challenges like margin declines and supply chain constraints, the company is well-positioned to capitalize on opportunities in spatial biology and proteomics markets.
By focusing on innovation, capacity investments, and addressing backlog delays, Bruker aims to sustain growth momentum and meet future demand expectations.
Overall, Bruker's strategic initiatives and market positioning indicate a positive outlook for continued growth and market leadership in the analytical instruments industry.

Bruker reports strong Q2 earnings, eyes global growth opportunities

Bruker's Q2 2023 performance reflects strong revenue and EPS growth, driven by demand across key segments and regions. The company's focus on innovation and global expansion positions it well for future growth.
While facing challenges such as high lead times and supply chain issues, Bruker is proactively managing costs and investing in capacity to meet demand. Opportunities for organic growth and profitability through strategic investments and pricing trends are on the horizon.
Overall, Bruker's Q2 2023 earnings call highlights a resilient performance, strategic strengths in R&D and global presence, challenges in capacity and logistics, and opportunities for sustained growth and profitability.

Bruker reports strong Q3 earnings and eyes sustainable growth

Bruker's Q3 2023 performance reflects robust revenue and earnings growth, supported by strong organic growth and strategic acquisitions.
While facing challenges in biopharma investments and China trends, Bruker's strengths lie in its elevated backlog and growth opportunities in green tech and academic funding.
The company's focus on high-end Life Science tools in China and long-term growth prospects position it well for sustained success.
Overall, Bruker's performance in Q3 2023 showcases resilience and strategic positioning for future growth.

Bruker excels in Q4 2023, eyes accelerated growth and acquisitions

Bruker's strong Q4 2023 performance showcased robust revenue and EPS growth, though challenges like margin pressure and geopolitical risks persist. With a focus on strategic acquisitions and market opportunities, Bruker aims for continued growth and innovation.

Bruker boosts revenue guidance after Q1 growth, faces margin challenges

Bruker's Q1 2024 performance showed growth despite margin challenges, with increased revenue guidance for the year.
Strong geographic revenue growth in the Americas and Europe contrasted with a decline in Asia Pacific.
Strategic acquisitions and focus on organic growth present opportunities for Bruker in 2024.
Challenges include margin compression, dilution from integration, and lower organic growth due to order distortions.

Bruker reports robust Q2 earnings, eyes growth in key sectors

Bruker's strong Q2 performance and strategic acquisitions are driving growth in key areas like spatial biology and molecular diagnostics.
While facing margin challenges due to recent acquisitions, the company remains confident in achieving operational excellence and margin expansion.
Maintaining mid-single-digit organic revenue growth and focusing on operational efficiency position Bruker for continued success in the market.
The company's outlook remains positive with opportunities for growth through acquisitions and market demand for its innovative solutions.

Bruker reports strong Q3 earnings, eyes margin expansion in 2025

Bruker's Q3 '24 performance was strong, with revenue growth and margin improvements.
Challenges include weaker-than-expected demand in biopharma and China markets.
Anticipated opportunities lie in margin expansion and innovative solutions in 2025.
Focus on driving improvements in acquired businesses to drive growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Bruker (BRKR) gains from several crucial product launches and acquisitions.

Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers

Bruker (BRKR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Bruker (BRKR) Rating Upgrade to Strong Buy

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

Cerner

McKesson

QIAGEN

The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.

QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical

Haemonetics

Penumbra

This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.

Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit

Computer Programs and Systems

Computer Programs and Systems' (CPSI ) move indicates its efforts to strengthen foothold in the healthcare information technology (HCIT) space.

Computer Programs and Systems to Offer Microsoft HealthVault

Ciena

Itron

Top Ranked Momentum Stocks to Buy for June 12th

Top Ranked Momentum Stocks to Buy for June 12th 2019

LHC Group

LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.

LHC Group Finalizes Joint Venture Agreement With AtlantiCare

CEO, President of Bruker Corp (NASDAQ:BRKR) Frank H Laukien sold 400,000 shares of BRKR on 06/03/2019 at an average price of $41.48 a share.

Bruker Corp (BRKR) CEO, President Frank H Laukien Sold $16.6 million of Shares

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Bruker (BRKR) Up 7.5% Since Last Earnings Report: Can It Continue?

CEO, President of Bruker Corp (NASDAQ:BRKR) Frank H Laukien sold 400,000 shares of BRKR on 05/30/2019 at an average price of $41.48 a share.

Bruker Corp CEO Sold $16.6 million of Shares

Masimo

NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.

Masimo's Technologies to be Deployed to Boost Pediatric Care

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bruker (BRKR) Upgraded to Buy: Here's What You Should Know

Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Bruker (BRKR) is a Solid Choice

Bruker Corporation (BRKR) CEO Frank Laukien on Q1 2019 Results - Earnings Call Transcript

Anemic second-quarter financials have investors reining in their expectations.

Why Bruker Jumped 12.6% Today

Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker (BRKR) Reports Next Week: What to Know Ahead of the Release

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Bruker (BRKR) is a Great Choice

Scientific instrument maker BRUKER Corporation announced Wednesday that it purchased RAVE LLC's semiconductor mask repair and cleaning business. 

Bruker Buys Photomask Repair Equipment Maker RAVE

Is Bruker (BRKR) a Solid Growth Stock? 3 Reasons to Think Yes

Bruker (BRKR) is progressing well with its three strategic buyouts, indicative of a majority interest in both Hain Diagnostics and Mestrelab along with the Alicona Imaging acquisition.

News for Bruker Stock (BRKR)